According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
A number of other equities research analysts also recently weighed in on the company. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Friday, August 16th. HC Wainwright reiterated a “buy” rating on shares of Dynavax Technologies in a report on Thursday, November 7th. Finally, BidaskClub raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $12.63.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.10). The company had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $10.31 million. Dynavax Technologies had a negative net margin of 519.95% and a negative return on equity of 399.60%. The company’s revenue was up 624.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) earnings per share. On average, equities analysts predict that Dynavax Technologies will post -2.04 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its position in shares of Dynavax Technologies by 225.0% during the first quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 11,387 shares in the last quarter. Wedbush Securities Inc. purchased a new stake in Dynavax Technologies in the second quarter valued at about $42,000. DekaBank Deutsche Girozentrale raised its stake in Dynavax Technologies by 32.3% in the second quarter. DekaBank Deutsche Girozentrale now owns 532,000 shares of the biopharmaceutical company’s stock valued at $2,054,000 after buying an additional 130,000 shares during the last quarter. C WorldWide Group Holding A S raised its stake in Dynavax Technologies by 100.7% in the second quarter. C WorldWide Group Holding A S now owns 996,412 shares of the biopharmaceutical company’s stock valued at $3,976,000 after buying an additional 500,000 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Dynavax Technologies by 4.2% in the second quarter. Swiss National Bank now owns 119,078 shares of the biopharmaceutical company’s stock worth $475,000 after acquiring an additional 4,800 shares in the last quarter. 82.36% of the stock is currently owned by institutional investors and hedge funds.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Featured Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.